Keywords: Merck & Co, vernakalanta, product application,

Merck & Co files MAA for vernakalant IV in Europe for atrial fibrillation

Article | 27 August 2009

Print This

US drug major Merck & Co, which operates in many countries as Merck Sharp & Dohme, says that the European Medicines Agency ( ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in